Posttransplantation lymphoproliferative disease (PTLDI is virtually always associated with Epstein-Barr virus (EBV) infection. BCL-2 and other proteins that confer resistance to apoptosis have been implicated in the pathogenesis of a variety of malignancies including lymphomas. One EBV protein, BHRF1, is a homologue of BCL-2, whereas another, the latency membrane protein 1 (LMP-l), upregulates BCL-2 expression in vitro. In the present study, we used immunohistochemistry to study the expression of these viral and cellular proteins as well as a variety of other EBV-encoded YMPHOPROLIFERATIVE disorders arising in immunosuppressed organ transplant recipients represent a spectrum of disorders ranging from polymorphic proliferations of lymphocytes through to monomorphic monoclonal proliferations of lymphocytes that exhibit the histologic features of non-Hodgkin's lymphoma. ' The term posttransplantation lymphoproliferative disorder (PTLD) has been applied to this spectrum of disorders.' Virtually all cases are associated with Epstein-Barr virus (EBV) infection and the virus is believed to play a central role in the pathogenesis of these disorders.
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Proteins that confer resistance to apoptosis are recognized as important in the development and progression of lymphomas. BCL-2, in particular, is expressed in a broad range of indolent lymphomas with and without the t( 14: 18) t r a n s l~c a t i o n .~.~ The EBV-encoded latent membrane protein-l (LMP1) that is commonly expressed in PTLD has been shown to upregulate BCL-2 expression in vitro.' Another EBV protein, BHRF1, has significant sequence and functional similarity to BCL-2. 
MATERIALS AND METHODS

Patients.
Lymphoproliferations from a total of 20 organ transplant recipients with a diagnosis of PTLD were studied. All but four patients (patients no. 3, 13, 14, and 15) received transplants and were diagnosed at a single institution (Loyola University, Chicago). Fourteen patients were cardiac recipients, 2 were renal recipients, 3 were single lung recipients, and 1 was a heart-lung recipient. Clinical data and flow cytometric analyses on a subset of these patients have been communicated else where'^" (Table l) .
Histopathology. Diagnosis was based on examination of histologic material obtained by open biopsy or by core needle biopsy in all cases. Lesions were classified according to the PTLD classification system recently described by Knowles et all2 and by the Working Formulation scheme whenever p~ssible.'~ Oral hairy leukoplakia specimens from 5 patients with human immunodeficiency virus (HIV) infection that have been previously reportedi4 were included as positive controls for the immunohistochemical detection of BHRFl expression. A histologically confirmed hairy leukoplakia lesion obtained from PTLD patient no. 2, 4 months before a YTLD diagnosis was similarly included as a positive control. Previously reported specimens from patients with EBV-associated Hodgkin's disease were used as positive controls for EBERl in situ hybridization and LMPl immunohistochemical detection." BHRFI antisera. Polyclonal rabbit antiserum against BHRFl was generated using a peptide corresponding to BHRFl amino acids 15 1 through 165 (STLIEDNIPGSRRFS). A cysteine residue was added to the C-terminus for linkage and D-tyrosine was added to the aminoterminus to prevent degradation. The peptide was linked to keyhole limpet hemocyanin and used for immunization as previously described." Section preparation. Specimens were obtained either as paraffin wax blocks or as frozen tissue samples. Paraffin wax sections were cut at 5 pm and attached to glass slides by incubation overnight at 60°C. Frozen sections were prepared at 6 /.m on a cryostat and then fixed for 20 minutes in acetone at 4°C. Frozen sections were stored at -40°C before immunostaining. All slides were pretreated with an adhesive (aminopropylethoxysilane) before sectioning.
In situ hybridization. The EBV status of all specimens was determined before immunohistochemistry using a standard digoxigeninbased in situ hybridization protocol for the detection of EBER-1, as previously described." Positive controls consisted of known EBVpositive Hodgkin's disease specimens and B95-8 cells grown as a tumor in SCID mice. Negative controls consisted of the use of an EBER-I sense probe.
1mmunohistolog.y. Indirect immunofluorescence was performed to evaluate the specificity of the BHRFl antisera. Slides were fixed with acetone and methanol, incubated in preinnoculation rabbit antiserum or in postinnoculation serum for 20 minutes at 1:400, washed again, and incubated with fluorescein isothiocyanate (FITC)-conjugated antirabbit antibody. Immunohistochemistry was performed for the detection of the cellular protein BCL-2 and a variety of EBV-encoded proteins including BHRFl, LMPl, EBNAI, EBNA2, and BZLFl. Paraffin wax sections were deparaffinized and transferred to Tris-buffered saline, pH 7.6 (TBS). Frozen sections were transferred directly to TBS.
The demonstration of some antigens in paraffin material required microwave pretreatment in 0.1 moVL citrate buffer, pH 6.0. The optimum microwave pretreatment times were determined for each antigen and are listed in Table 2 . After pretreatment, endogenous peroxidase activity was blocked in 0.3% hydrogen peroxide in methanol and sections were transferred to TBS.
Sections were then incubated in primary antibodies at optimum dilutions previously determined for each antibody ( Table 2 ). All primary antibodies were diluted in 10% normal sheep serum. Mouse monoclonal antibodies and the rabbit polyclonal serum to BHRFl were detected using the peroxidase-based Dako Duet system (Dako Ltd catalog no. K492; Dako, Glostrup, Denmark). The rat monoclonal antibodies to EBNAl, IH4-1 and 2B4-1, were detected using rabbit antirat Igs (Dako Ltd catalog no. Z455) at a dilution of 1:400, followed by the Dako Duet system. Peroxidase activity was visualized using the standard diaminobenzidine reaction.
Positive controls for EBV-encoded antigens consisted of paraffin sections of pelleted B95-8, X50-7, and BJAB cells; paraffin and frozen sections of an LCL gown as a SCID mouse tumor; and EBVpositive Hodgkin's disease specimens. Normal tonsil served as a control for BCL-2 expression. Negative controls consisted of the substitution of primary antibodies with appropriate nonimmune serum. l g gene rearrangement studies. DNA analysis for clonal Ig-gene rearrangements was performed on tumor specimens whenever technically feasible using standard technique^.".'^ 
RESULTS
In situ hybridization. The EBV association in this series of PTLD cases was confirmed by EBER in situ hybridization.
The EBERs are abundant RNA polymerase I I I transcripts expressed in many EBV-associated tumors even when there is very limited viral protein expression?' EBER-1 RNA was detected in 19 of 20 histologically confirmed cases of PTLD ( Table 3 ). The single EBER-negative specimen (patient no. 20) was a necrotic needle biopsy of lymph node. Subsequently, immunohistochemical analysis showed the presence of latent gene products in the tumor cells of this lesion, thus implying poor preservation of RNA rather than a true ab- toplasmic immunofluorescence, whereas no immunofluorescence was seen with cells incubated in preinnoculation serum or in cells transfected with the control plasmid (data not shown). The sensitivity of the antiserum for detecting BHRFl in conventionally fixed surgical specimens was evaluated by staining formalin-fixed paraffinembedded EBV(-) and EBV(+) cell lines. In assays of a B-cell lymphoma Line that does not contain EBV (BJAB), no signal was detected. In assays of an EBV(+) B-cell line with low-level lytic infection (B95-8), B H W l signal was detected in approximately 5% to 10% of cells (Fig 1A) . This percentage is similar to that identified as lytically infected by immunohistochemical detection of the immediate early lytic protein BZLFl (Fig 1B) and is consistent with the classification of BHRFl as a lytic cycle protein. The sutiability of the antisera to detect BHRFl in fixed tissues was further confirmed by studying oral hairy leukoplakia specimens. In formalin-fixed paraffin-embedded specimens from 6 patients (patient no. 2 with PTLD and 5 patients with HIV infection and no lymphoproliferative disease), BHRFl signal was detected in the upper layers of the epithelium. The signal was localized to the cytoplasm of positive cells and staining was characteristically granular in appearance ( Fig  1C) . The presence of EBV lytic gene expression in the upper layers of epithelium was confirmed in each case by the detection of BZLFl (data not shown).
In PTLD lesions, immunohistochemistry with BHRFl antiserum showed no staining of tumor cells. Nonspecific staining of macrophages seen in many cases was easily distinguished from the granular staining observed in control specimens.
BCL-2 detection. Immunohistochemistry for BCL-2 showed positive staining of tumor cells in 12 of 17 cases. In all positive cases staining was cytoplasmic and most tumor cells were stained (Fig 1D) . In addition, all specimens showed strong BCL-2 staining of small noninvolved lymphocytes (Fig 1E) serving as a useful internal control in those cases in which BCL-2 could not be shown in the tumor cell population. In 1 case (patient no. 20) showing only a scattered tumor cell infiltrate, it was not possible to determine whether BCL-2 was being expressed in the tumor cell population or in surrounding noninvolved lymphocytes. This case was therefore not included in the analysis.
LMPI. L W 1 was detected in a total of 16 of 20 cases and in a varying proportion of the tumor cells (Fig 2A) . In 1 case (patient no. 3) the absence of L W 1 expression in paraffin material was coniirmed later on acetone-fixed frozen sections. LMPl and BCL-2 were commonly expressed in the same cases. Thus, of the 16 cases in which L W 1 was For personal use only. on September 14, 2017. by guest www.bloodjournal.org From shown, all but 1 expressed detectable levels of BCL-2 in the tumor cell population and all 4 LMP1-negative cases were also BCL-2 negative. EBNA2 was detected in the nuclei of tumor cells in 15 of 20 cases ( Fig 2B) and with 1 exception (patient no. 5) was coexpressed with LMP1.
EBNAI. Nineteen of 20 PTLD cases expressed detectable levels of EBNA1. In most cases, the majority of tumor cells were stained, although there was variation from case to case and in general more cells were stained with the 2B4-1 antibody than with the 1H4-1 reagent. Positive staining was granular and confined to the nucleus of tumor cells ( Fig  2C) . BZLFl protein was detected in tumor specimens from 19 of 20 patients. In most cases, only occasional tumor cells were positive; however, in several patients, much greater numbers of the tumor cell population were stained (Fig 2D) .
DISCUSSION
Proteins that inhibit apoptosis in tumors may enhance tumor cell survival and facilitate tumor progession. The association of EBV with a variety of malignancies and homology of a viral protein with BCL-2 suggested the possibility that BHRFl might be expressed in PTLD lesions. However, in the set of tumors examined here, we could find no evidence of BHRFl expression. The BHRFl gene contains several BZLFl binding sites upstream of the coding sequence" and is transcriptionally upregulated by BZLFl in vitro. However, even in PTLD lesions showing large numbers of cells expressing BZLF1, we detected no BHRFl expression. Failure to detect BHRFl expression in tumors expressing BZLFl suggests that in vivo BZLFl expression is insufficient to bring about BHRFl expression in PTLD lesions. This is consistent with the recent report that BZLFl alone is not able to activate full lytic cycle in EBV lymphoblastoid cell lines, in contrast with EBV Burkitt's lymphoma cell lines. 22 In contrast, we did detect evidence of BHRFl expression in oral hairy leukoplakia showing the ability to detect the antigen in clinical specimens.
In contrast to its viral homologue, BCL-2 is commonly expressed in PTLD. Whereas in follicular lymphomas BCL-2 expression is driven by a chromosomal translocation, such 14-18 translocations are generally absent in PTLD. '2,23 In many other indolent B-cell tumors, BCL-2 expression is also upregulated in the absence of the 14-18 chromosomal translocation. The data presented here showing a high concordance between LMPl expression and BCL-2 expression are consistent with the hypothesis that LMPl expression drives BCL-2 expression in a subset of these lymphomas as it does in B cells in vitro.
A possible relationship between LMPl and EBV expression has also been investigated in other EBV-associated tumors. As in PTLD, a consistent association has been reported in acquired immunodeficiency syndrome (AIDS) primary central nervous system lymphoma^,^^ but no association has been shown in nasopharyngeal c a r c i n~m a ,~~ Hodgkin's disease,26-30 or AIDS-associated systemic lymphoma^.^' These seemingly disparate results may be reconciled in the light of in vitro evidence that the LMP1-BCL-2 relationship is cell type specific and has only been shown in a subset of B cells.'' The results of this study confirm previous reports documenting the heterogeneity of PTLD both with respect to its histopathological appearan~e",'~ and the pattern of EBV gene expression."-37 Coexpression of EBNA2 and LMPl in the majority of cases in this series suggests an unrestricted pattern of viral latency antigen expression similar to that recognized in lymphoblastoid cell lines. In other cases, the pattern resembled that seen in EBV-associated Burkitt's lymphoma with expression of EBNAl alone.3K A single case showed expression of LMPl but not EBNA2, suggesting a form of latency paralleling that in EBV-associated Hodgkin's disease, some cases of nasopharyngeal carcinoma, and some EBV lymphomas in AIDS patients."-43 BZLFl has been detected in this and other ~eries.'~.'~ The importance of lytic cycle expression in the biology of these tumors remains unclear.
